Morgan G W, Freeman A P, McLean R G, Jarvie B H, Giles R W
Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1925-31. doi: 10.1016/0360-3016(85)90273-1.
Cardiac, thyroid and pulmonary function were evaluated in 25 patients aged 35 years or under, treated for Hodgkin's disease by mantle radiotherapy 5-16 years previously. No patient had symptoms of heart disease. Although thallium myocardial perfusion scintigraphy was normal in all patients, abnormalities of myocardial function were detected in 6 (24%) patients using gated equilibrium rest and exercise radionuclide ventriculography. Resting left ventricular ejection fraction (LVEF) was abnormal in 1 patient, and in 3 patients there was an abnormal LVEF response to exercise. All 6 patients had right ventricular dilatation. Apical hypokinesia was present in 4 of these patients. A small asymptomatic pericardial effusion was detected by M-Mode echocardiography in only 2 (8%) patients. Twenty-three (92%) patients had evidence of abnormal thyroid function. Two (8%) patients had become clinically hypothyroid. Serum TSH was elevated in 13 (52%) patients and TRH stimulation test was abnormal in a further 10 (40%) patients in whom TSH was normal. Pulmonary function studies showed a moderate decrease in diffusing capacity (72% of predicted) and a minor reduction in lung volume. Although a high incidence of cardiac, thyroid and pulmonary abnormalities was detected, only the 2 patients who had become hypothyroid were symptomatic. Modification of the irradiation technique may reduce the incidence of cardiac abnormalities, but is unlikely to alter significantly the thyroid or pulmonary sequelae.
对25例年龄在35岁及以下、5至16年前接受斗篷式放射治疗霍奇金病的患者进行了心脏、甲状腺和肺功能评估。所有患者均无心脏病症状。尽管所有患者的铊心肌灌注闪烁显像均正常,但使用门控平衡静息和运动放射性核素心室造影在6例(24%)患者中检测到心肌功能异常。1例患者静息左心室射血分数(LVEF)异常,3例患者运动时LVEF反应异常。所有6例患者均有右心室扩张。其中4例患者存在心尖运动减弱。仅2例(8%)患者通过M型超声心动图检测到少量无症状心包积液。23例(92%)患者有甲状腺功能异常的证据。2例(8%)患者出现临床甲状腺功能减退。13例(52%)患者血清促甲状腺激素(TSH)升高,另外10例(40%)TSH正常的患者促甲状腺激素释放激素(TRH)刺激试验异常。肺功能研究显示弥散能力中度下降(为预测值的72%),肺容积轻度减少。尽管检测到心脏、甲状腺和肺部异常的发生率较高,但只有2例出现甲状腺功能减退的患者有症状。修改放疗技术可能会降低心脏异常的发生率,但不太可能显著改变甲状腺或肺部后遗症。